ATARA BIOTHERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5609 USD | -1.28% |
|
-10.11% | +9.38% |
| May. 20 | Sector Update: Health Care Stocks Ease Monday Afternoon | MT |
| May. 20 | Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise | MT |
Financials (USD)
| Sales 2024 * | 115M | Sales 2025 * | 78.73M | Capitalization | 67.54M |
|---|---|---|---|---|---|
| Net income 2024 * | -84M | Net income 2025 * | -106M | EV / Sales 2024 * | 0.42 x |
| Net cash position 2024 * | 19.23M | Net cash position 2025 * | 88.14M | EV / Sales 2025 * | -0.26 x |
| P/E ratio 2024 * |
-0.85
x | P/E ratio 2025 * |
-0.7
x | Employees | 173 |
| Yield 2024 * |
357% | Yield 2025 * |
357% | Free-Float | 90.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on Atara Biotherapeutics, Inc.
More recommendations
More press releases
| 1 day | -1.28% | ||
| 1 week | -10.11% | ||
| 1 month | -18.71% | ||
| 3 months | -27.90% | ||
| 6 months | -15.02% | ||
| Current year | +9.38% |
1 week
0.55
0.66
1 month
0.480.73
Current year
0.431.58
1 year
0.202.54
3 years
0.2020.04
5 years
0.2028.20
10 years
0.2065.56
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Touchon
CEO | Chief Executive Officer | 61 | 19-06-23 |
Eric Hyllengren
DFI | Director of Finance/CFO | 49 | 17-12-31 |
Anhco Nguyen
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Carol Gallagher
CHM | Chairman | 59 | 12-12-31 |
Eric Dobmeier
BRD | Director/Board Member | 55 | 15-03-25 |
William Heiden
BRD | Director/Board Member | 64 | 15-11-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 0 M€ | 0.00% | - | |
| 0.03% | 430 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 0.5609 | -1.28% | 1,079,187 |
| 24-05-30 | 0.5682 | +1.46% | 887,949 |
| 24-05-29 | 0.56 | -8.42% | 1,433,488 |
| 24-05-28 | 0.6115 | -2.00% | 953,171 |
| 24-05-24 | 0.624 | -4.00% | 762,283 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Companyâs T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Calendar
2024-08-04
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
0.5609
USD
Average target price
5.233
USD
Spread / Average Target
+833.02%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.38% | 67.54M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- ATRA Stock
